Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 vs bevacizumab plus FOLFOX as second-line therapy in metastatic colorectal cancer
2005-003443-31Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cediranib in metastatic colon cancer (mCRC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Oct 2005; status: completed.
02
Drugs
cediranib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2005-003443-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003443-31.